NAMPT and obesity disorder: Indeed, visfatin did impair microvascular relaxation from a concentration of 25–50 ng/mL, which can be found in the circulation of patients suffering from obesity, type 2 diabetes or chronic kidney disease, whereas their matched healthy controls exhibit lower levels [11], [18], [19].